drugset

drugset / Trial / NCT00346294

An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis

NCT00346294 ↗

Phase 4 Completed 115 enrolled Amgen Immunex Corporation · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label, single arm study to estimate the rate of failure of the Enbrel® SureClick™ Auto-injector in RA subjects.

Timeline

Start: 2006-01
Primary completion: 2006-03
Completion: 2006-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Etanercept	Protein / enzyme biologic	—	—

Indications